Skip to main content

and
  1. Article

    Open Access

    Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model

    The development of new treatment agents in recent decades has significantly improved the survival of patients with multiple myeloma (MM). Nonetheless, MM remains an incurable disease; therefore, novel combinat...

    Jaya Lakshmi Thangaraj, Sung-Hoon Jung, Manh-Cuong Vo in Cancer Immunology, Immunotherapy (2023)

  2. No Access

    Article

    Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21

    Natural killer (NK) cell-based immunotherapy is a promising treatment approach for multiple myeloma (MM), but obtaining a sufficient number of activated NK cells remains challenging. Here, we report an improve...

    Jaya Lakshmi Thangaraj, Minh-Trang Thi Phan in Cancer Immunology, Immunotherapy (2022)

  3. No Access

    Article

    Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

    Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated th...

    Seo-Yeon Ahn, Hwa Kyung Park, Joon Ho Moon in International Journal of Hematology (2021)